Cocrystal Pharma Inc.
| NASDAQ: COCP | Healthcare / Biotechnology / USA |
| 1.90 | -0.0800 | -4.04% | Vol 9.40K | 1Y Perf 582.76% |
| Sep 22nd, 2023 15:56 DELAYED |
| BID | 1.90 | ASK | 1.94 | ||
| Open | 1.98 | Previous Close | 1.98 | ||
| Pre-Market | - | After-Market | 1.96 | ||
| - - | 0.06 3.16% |
| Target Price | 37.06 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.85K | Finscreener Ranking | ★★★★★ 59.87 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★+ 53.99 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★★+ 56.28 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 7.29 | Earnings Rating | Strong Buy | |
| Market Cap | 19.33M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.35 | |
| Beta | 1.20 |
Today's Price Range 1.902.04 | 52W Range 1.743.93 | 5 Year PE Ratio Range -50.30-2.00 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.04% | ||
| 1 Month | -34.48% | ||
| 3 Months | -20.83% | ||
| 6 Months | 3.26% | ||
| 1 Year | 582.76% | ||
| 3 Years | 99.73% | ||
| 5 Years | -31.65% | ||
| 10 Years | -90.69% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -21.15 | |||
ROE last 12 Months | -67.57 | |||
ROA (5Y Avg) | -22.29 | |||
ROA last 12 Months | -65.77 | |||
ROC (5Y Avg) | -37.71 | |||
ROC last 12 Months | -60.41 | |||
Return on invested Capital Q | -12.12 | |||
Return on invested Capital Y | -4.62 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 0.39 | ||||
| 132.06 | ||||
| 54.20 | ||||
| -1.00 | ||||
| -2.39 | ||||
| 0.39 | ||||
| 5.39 | ||||
| -24 432 800.00 | ||||
| Forward PE | -1.09 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 26.00 | ||||
| 27.70 | ||||
| 0.00 | ||||
| 0.01 | ||||
| -19 009.50 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 350.40 | ||||
| -2 276.70 | ||||
| - | ||||
| -5.26 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.53 | -0.50 | 5.66 |
| Q01 2023 | -0.59 | -0.64 | -8.47 |
| Q04 2022 | -0.72 | -0.55 | 23.61 |
| Q03 2022 | -0.49 | -0.70 | -42.86 |
| Q02 2022 | -0.48 | -0.48 | 0.00 |
| Q01 2022 | -0.48 | -0.48 | 0.00 |
| Q04 2021 | -0.48 | -0.48 | 0.00 |
| Q03 2021 | -0.48 | -0.48 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.47 | 6.00 | Positive |
| 12/2023 QR | -0.53 | -12.77 | Negative |
| 12/2023 FY | -2.03 | 4.69 | Positive |
| 12/2024 FY | -1.81 | -9.70 | Negative |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.47 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 9.40K |
| Shares Outstanding | 10.17K |
| Shares Float | 6.98M |
| Trades Count | 120 |
| Dollar Volume | 18.50K |
| Avg. Volume | 31.54K |
| Avg. Weekly Volume | 22.70K |
| Avg. Monthly Volume | 41.12K |
| Avg. Quarterly Volume | 30.78K |
Cocrystal Pharma Inc. (NASDAQ: COCP) stock closed at 1.9 per share at the end of the most recent trading day (a -4.04% change compared to the prior day closing price) with a volume of 9.40K shares and market capitalization of 19.33M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Cocrystal Pharma Inc. CEO is Gary L. Wilcox.
The one-year performance of Cocrystal Pharma Inc. stock is 582.76%, while year-to-date (YTD) performance is -2.56%. COCP stock has a five-year performance of -31.65%. Its 52-week range is between 1.74 and 3.934788, which gives COCP stock a 52-week price range ratio of 7.29%
Cocrystal Pharma Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.39, a price-to-sale (PS) ratio of 132.06, a price to cashflow ratio of 54.20, a PEG ratio of -, a ROA of -65.77%, a ROC of -60.41% and a ROE of -67.57%. The company’s profit margin is -5.26%, its EBITDA margin is -2 276.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cocrystal Pharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.47 for the next earnings report. Cocrystal Pharma Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Cocrystal Pharma Inc. is Strong Buy (1), with a target price of $37.06, which is +1 850.53% compared to the current price. The earnings rating for Cocrystal Pharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cocrystal Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cocrystal Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.91, ATR14 : 0.19, CCI20 : -75.29, Chaikin Money Flow : -0.63, MACD : -0.21, Money Flow Index : 14.71, ROC : -23.69, RSI : 28.47, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 19.05, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cocrystal Pharma Inc. in the last 12-months were: Phillip Frost (Buy at a value of $2 000 001)
Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
CEO: Gary L. Wilcox
Telephone: +1 786 459-1831
Address: 19805 North Creek Parkway, Bothell 98011, WA, US
Number of employees: 11
